PurposeTo cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of
tumor hypoxia with intrinsic susceptibility MRI measurements and to
demonstrate the feasibility of translation of the technique for
patients.Materials and MethodsPreclinical studies in nine 786–0-R renal cell carcinoma (RCC)
xenografts and prospective clinical studies in eight patients with RCC
were performed. Longitudinal relaxation rate changes (∆R1) after
100% oxygen inhalation were quantified, reflecting the paramagnetic
effect on tissue protons because of the presence of molecular oxygen.
Native transverse relaxation rate (R2*) and oxygen-induced R2*
change (∆R2*) were measured, reflecting presence of
deoxygenated hemoglobin molecules. Median and voxel-wise values of
∆R1 were compared with values of R2* and ∆R2*.
Tumor regions with dynamic contrast agent–enhanced MRI perfusion,
refractory to signal change at OE MRI (referred to as perfused Oxy-R),
were distinguished from perfused oxygen-enhancing (perfused Oxy-E) and
nonperfused regions. R2* and ∆R2* values in each tumor
subregion were compared by using one-way analysis of variance.ResultsTumor-wise and voxel-wise ∆R1 and ∆R2* comparisons did
not show correlative relationships. In xenografts, parcellation analysis
revealed that perfused Oxy-R regions had faster native R2* (102.4
sec–1 vs 81.7 sec–1) and greater
negative ∆R2* (−22.9 sec–1 vs
−5.4 sec–1), compared with perfused Oxy-E and
nonperfused subregions (all P < .001),
respectively. Similar findings were present in human tumors
(P < .001). Further, perfused Oxy-R helped
identify tumor hypoxia, measured at pathologic analysis, in both
xenografts (P = .002) and human tumors
(P = .003).ConclusionIntrinsic susceptibility biomarkers provide cross validation of the OE
MRI biomarker perfused Oxy-R. Consistent relationship to pathologic
analyses was found in xenografts and human tumors, demonstrating
biomarker translation.Published under a CC BY 4.0 license.Online
supplemental material is available for this
article.